How to Value an Orthopedic or Spine Practice in 2026

Orthopedic practices sit at the top of the physician practice valuation hierarchy, and it's not close. A five-surgeon ortho group with an ASC interest and in-house imaging can generate $8-15M in revenue with EBITDA margins that make PE firms salivate. I've been involved in orthopedic transactions ranging from solo sports medicine physicians selling to hospital systems to large multi-specialty ortho platforms recapitalizing with private equity at 12x+ EBITDA. The valuation dynamics are unlike any other physician specialty.

Why Orthopedics Commands Premium Valuations

The answer comes down to one word: ancillaries. Orthopedic surgeons generate revenue from multiple streams that most physician specialties cannot replicate. Professional fee collections are just the starting point. Add in ASC facility fees, imaging (MRI, X-ray, CT), physical therapy, durable medical equipment (DME), and injectable/biologic revenue, and you have a practice that generates $2-4M per surgeon in total enterprise revenue — compared to $600K-$1M for a primary care physician.

This ancillary stack is what separates orthopedics from general medical practices. A primary care group valued at 4-6x EBITDA is doing well. An ortho group with a fully developed ancillary platform can clear 8-15x EBITDA in the current market.

The Two Valuation Frameworks

How your ortho practice gets valued depends entirely on its size, structure, and buyer type.

Solo practitioners and small groups (1-3 surgeons) without significant ancillary ownership typically sell on a collections-based or SDE methodology. Expect 3-5x SDE or 50-75% of collections. The buyer is usually a hospital system, a larger ortho group, or occasionally a PE platform looking for a tuck-in. At this level, the practice is really a book of business — surgical case volume tied to specific surgeons.

Multi-surgeon groups (4+ surgeons) with ancillary revenue sell on an EBITDA basis, and this is where valuations get compelling. The enterprise EBITDA includes the practice's share of ASC distributions, imaging center profits, PT revenue, and DME margins. Multiples range from 8-12x EBITDA for platform acquisitions to 5-8x EBITDA for bolt-on additions to existing PE platforms.

At the top end — large ortho groups with dominant market position, owned ASCs, and 10+ surgeons — I've seen transactions close at 12-15x EBITDA. HOPCo, US Physical Therapy, and the major PE-backed orthopedic platforms have pushed pricing to historic highs.

The ASC Factor: Where the Real Value Lives

Ambulatory surgery center ownership is the single biggest value driver in orthopedic M&A. An ortho group that owns (or has significant equity in) its ASC captures facility fees that would otherwise go to a hospital. For total joint replacements, spine cases, and sports medicine procedures, ASC facility fees can equal or exceed the surgeon's professional fee.

Consider the math: a surgeon performing 400 cases per year at a hospital generates $1.2M in professional fee collections. That same surgeon performing 250 of those cases in an owned ASC generates the same $1.2M in professional fees plus $600-800K in ASC distributions. The practice-level economics are transformative.

Buyers evaluate ASC ownership meticulously. They want to know: What's your ownership percentage? Is it a single-specialty or multi-specialty ASC? What's the case volume trend? Are total joints being migrated to outpatient (the answer should be yes)? What does the management agreement look like? Is there a hospital partner, and what are the governance terms?

An ortho practice with a 60% ASC interest is worth dramatically more than the same practice referring cases to an unrelated ambulatory surgery center. The ASC distributions flow through to enterprise EBITDA, and at a 10x multiple, every dollar of ASC profit adds $10 of enterprise value.

Ancillary Revenue: The Compliance Trap

Here's where I've seen deals go sideways. Ancillary revenue in orthopedics — imaging, PT, DME, biologics — is under intense regulatory scrutiny. Stark Law and the Anti-Kickback Statute impose strict rules on self-referral arrangements. Buyers and their attorneys will dissect your ancillary structure during due diligence.

The questions that will come up: Is your in-house PT operation structured as a compliant in-office ancillary services (IOAS) exception? Are your DME arrangements with manufacturers at fair market value? Do your biologic/injectable arrangements involve any volume-based pricing or rebates that could be characterized as kickbacks? Is your imaging center structured to survive a Stark audit?

I cannot stress this enough: non-compliant ancillary structures don't just reduce value — they kill deals entirely. Sophisticated PE buyers will walk away from a $20M transaction if they smell regulatory risk in the ancillary stack. Get a healthcare regulatory attorney to review your ancillary arrangements 12-18 months before going to market.

Surgical Case Volume and Subspecialty Mix

Not all orthopedic cases are valued equally by buyers. The subspecialty mix of your practice directly impacts valuation because it determines revenue per case, ASC migration potential, and growth trajectory.

Total joints (hip and knee replacement) are the highest-value cases. CMS continues to expand the list of procedures eligible for ASC reimbursement, and total joint volume in ASCs is growing 20-30% annually. Surgeons doing high-volume total joints in an ASC setting are the most sought-after acquisition targets.

Spine surgery commands premium valuations when performed at an ASC. Lumbar fusions, disc replacements, and decompression procedures generate significant facility fees. However, buyer appetite varies — some PE platforms actively seek spine, others avoid it due to malpractice exposure and payer pushback on outpatient migration.

Sports medicinehas high volume and good demographics (young, active patients with commercial insurance) but lower revenue per case than joints or spine. It's excellent for building patient volume and referral networks.

Workers' compensation and auto injurycases deserve special mention. These payers typically reimburse at higher rates than commercial insurance, and practices with significant work comp/auto volume often have higher revenue per case. Buyers value this payer mix favorably, though they'll scrutinize the concentration and long-term sustainability.

The Active Buyer Landscape

Orthopedic M&A is one of the most active physician practice segments in 2026. The major buyer categories:

• PE-backed orthopedic platforms: HOPCo (Linden Capital), OrthoNow, Ortho Alliance, and others. They acquire platform groups at 10-15x EBITDA and bolt-on smaller practices at 5-8x.
• Hospital systems: Still active but increasingly unable to compete with PE pricing. They offer employment models with lower upfront value but more stability.
• National ASC operators: SCA Health (Optum), USPI (Tenet), and Amsurg/Envision have orthopedic surgery center strategies that involve acquiring the practice alongside the ASC interest.
• US Physical Therapy and PT platforms: Acquiring ortho groups with integrated PT operations to build referral networks and capture downstream revenue.

What Destroys Orthopedic Practice Value

Surgeon concentration.If one surgeon generates 50%+ of collections, that's an enormous key-person risk. If that surgeon is also the majority ASC stakeholder, the problem compounds. Buyers will either require extended employment agreements (5-7 years) or discount the valuation significantly.

Hospital exclusivity conflicts.Many orthopedic surgeons hold medical directorships, call coverage agreements, or exclusive service arrangements with hospitals. These can create post-acquisition conflicts when a PE buyer wants to shift cases to the practice's ASC. Review all hospital agreements for non-compete and exclusivity clauses before going to market.

Aging surgeon demographics without succession. An ortho group where the senior partners are 60+ with no mid-career surgeons joining the practice is a ticking clock. Buyers are acquiring future case volume, not just current production. A practice that will lose 40% of its surgical capacity to retirement within 5 years has a value problem.

Declining surgical case volume. The trend line matters more than the absolute number. Three years of declining cases — whether from surgeon aging, competitor entry, or payer shifts — will significantly reduce buyer interest and pricing.

The Bottom Line

Orthopedic practices are among the most valuable physician practices in M&A today, but the range is wide. A solo sports medicine doc selling to a hospital system might get 3x SDE. A ten-surgeon multi-specialty ortho group with ASC ownership, in-house imaging, and integrated PT can command 12-15x EBITDA. The difference is ancillary development, surgeon bench depth, and market positioning. If you're 3-5 years from a transaction, the highest-return investments are developing your ASC, building your ancillary platform (compliantly), and recruiting mid-career surgeons who give buyers confidence in the practice's long-term production capacity.